Clinical trial
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in…
NCT00480025 · GlaxoSmithKline, Industry · Terminated
Key facts
| NCT number | NCT00480025 |
|---|---|
| Title | GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer |
| Official title | GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lung Cancer, Non-Small Cell |
| Intervention type | Biological |
| Interventions | GSK1572932A Antigen-Specific Cancer Immunotherapeutic, Placebo Control |
| Enrollment | 2,278 |
| Start date | Oct 4, 2007 |
| Primary completion | Dec 6, 2013 |
| Completion | Sep 23, 2014 |
| First posted | May 30, 2007 |
| Last update posted | Dec 22, 2020 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czechia, Estonia, Finland, France, Germany and 22 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: